Adaptive Biotechnologies Corporation Adaptive Biotechnologies (ADPT) shares are trading higher Tuesday after the company announced plans to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses. The move, disclosed Monday, comes as both segments have hit key milestones—MRD is now profitable and expanding its clinical use, while Immune Medicine has built a powerful drug discovery platform.
The commercial-stage biotech is exploring strategic options for its Immune Medicine unit, which has made strides in identifying disease-causing T-cell receptors and their antigens. With over 6 million functional TCR-antigen pairs and well-characterized data on more than 10,000 patients, the unit is a treasure trove for drug developers. Adaptive expects to finalize the separation path by the end of 2026, aiming to unlock value for shareholders.
MRD, the company's cash cow, has seen revenue surge from $103 million in 2023 to $212 million in 2025, and it reported $15 million in adjusted EBITDA last year. The clonoSEQ test is now embedded in routine clinical practice and drug development, covering more than 300 million lives, integrated into over 175 EMR accounts, and used in more than 180 active biopharma trials.
Analyst Consensus & Recent Actions: The stock carries a Buy rating with an average price target of $20.20. Recent analyst moves include:
- Morgan Stanley: Equal-Weight (Lowers Target to $18.00) (May 12)
- JP Morgan: Overweight (Lowers Target to $19.00) (May 6)
- TD Cowen: Buy (Raises Target to $21.00) (May 6)
Momentum Check: Adaptive's momentum score is bullish at 85.47, indicating the stock is outperforming the broader market despite recent price dips. The company's strategic separation could be a catalyst to watch.
Stock Price: Adaptive Biotechnologies shares were up 0.74% at $17.59 at the time of publication Tuesday.
